Insmed’s Amikacin Faces US FDA Questions On Surrogate Endpoint, Target Population

 
• By Sue Sutter
  
Mycrobacteria_686575531_1200.jpg
Insmed seeks approval for adults with nontuberculous mycobacterial lung disease caused by Mycobaterim avium complex.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers